CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 
 
 


Enanta Pharmaceuticals Inc  (ENTA)
Other Ticker:  
 
    Sector  Healthcare    Industry Major Pharmaceutical Preparations
 
 

ENTA's Revenue Growth by Quarter and Year

Enanta Pharmaceuticals Inc's Revenue results by quarter and year




ENTA Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter September - 75.93 12.84 14.42
III Quarter June 57.26 7.51 13.98 11.60
II Quarter March 44.05 8.96 13.00 57.37
I Quarter December 38.11 10.42 48.45 77.50
FY   139.42 102.82 88.27 160.89



ENTA Revenue third quarter 2018 Y/Y Growth Comment
Enanta Pharmaceuticals Inc reported Revenue surge of 662.48% year on year in the third quarter, to $ 57.26 millions, this is lower than Enanta Pharmaceuticals Inc's recent average Revenue surge of 861.02%.

Looking into third quarter results within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Revenue growth. While Enanta Pharmaceuticals Inc' s Revenue doubling of 662.48% ranks overall at the positon no. 56 in the third quarter.




ENTA Revenue ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter September - 491.36 % -10.96 % 446.21 %
III Quarter June 662.48 % -46.28 % 20.52 % -72.41 %
II Quarter March 391.63 % -31.08 % -77.34 % 2556.02 %
I Quarter December 265.74 % -78.49 % -37.48 % 8607.87 %
FY   - 16.48 % -45.14 % -

Financial Statements
Enanta Pharmaceuticals Inc's third quarter 2018 Revenue $ 57.26 millions ENTA's Income Statement
Enanta Pharmaceuticals Inc's third quarter 2017 Revenue $ 7.51 millions Quarterly ENTA's Income Statement
New: More ENTA's historic Revenue Growth >>


ENTA Revenue (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter September - 911.05 % -8.15 % 24.31 %
III Quarter June 29.99 % -16.18 % 7.54 % -79.78 %
II Quarter March 15.59 % -14.01 % -73.17 % -25.97 %
I Quarter December -49.81 % -18.85 % 235.99 % 2835.61 %
FY (Year on Year)   - 16.48 % -45.14 % -




Revenue third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #21
Overall #56
Revenue Y/Y Growth Statistics
High Average Low
8578.39 % 861.02 % -90.97 %
(Dec 31 2014)   (Sep 30 2014)

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018
You need to upgrade your Flash Player

Enanta Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #84
Overall #260
Revenue Q/Q Growth Statistics
High Average Low
2838.87 % 346.88 % -96.94 %
(Dec 31 2014)  


ENTA's III. Quarter Q/Q Revenue Comment
Enanta Pharmaceuticals Inc achieved in the III. Quarter 2018 below company average Revenue jump of 29.99% quarter on quarter, to $ 57.26 millions.

III. Quarter 2018 Enanta Pharmaceuticals Inc's Revenue Q/Q growth were a mixed bag, even if beneath the ordinary, yet it demonstrates absolute improvement relative to the -16.18% in the III. Quarter 2017.

Within Major Pharmaceutical Preparations industry 35 other companies have achieved higher Revenue quarter on quarter growth. While Enanta Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 260.


Enanta Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
12 Months Ending
(Jun 30 2017)
Cumulative Revenue 12 Months Ending $ 215.35 $ 165.60 $ 130.51 $ 102.81 $ 39.73
Y / Y Revenue Growth (TTM) 442.05 % 258.47 % 159.77 % 16.48 % -55.78 %
Year on Year Revenue Growth Overall Ranking # 25 # 98 # 129 # 1041 # 2948
Seqeuential Revenue Change (TTM) 30.04 % 26.89 % 26.93 % 158.79 % -14 %
Seq. Revenue Growth (TTM) Overall Ranking # 138 # 172 # 371 # 22 # 3759




Cumulative Revenue growth Comment
With 442.05% annual Revenue growth, Enanta Pharmaceuticals Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2018.

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 25, from total ranking in previous quarter at 98.

Revenue TTM Q/Q Growth Statistics
High Average Low
160.46 %
22.72 %
-43.08 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 19
Healthcare Sector # 10
Overall # 25

Revenue TTM Y/Y Growth Statistics
High Average Low
442.05 %
108.42 %
-61.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 45
S&P 500 # 138


You need to upgrade your Flash Player




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ENTA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for ENTA's Competitors
Revenue Growth for Enanta Pharmaceuticals Inc's Suppliers
Revenue Growth for ENTA's Customers

You may also want to know
ENTA's Annual Growth Rates ENTA's Profitability Ratios ENTA's Asset Turnover Ratio ENTA's Dividend Growth
ENTA's Roe ENTA's Valuation Ratios ENTA's Financial Strength Ratios ENTA's Dividend Payout Ratio
ENTA's Roa ENTA's Inventory Turnover Ratio ENTA's Growth Rates ENTA's Dividend Comparisons



Companies with similar Revenue surge for the quarter ending Jun 30 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2018
Dynavax Technologies Corp  1,094.29 %$ 1,094.286 millions
United Cannabis Corp  1,034.34 %$ 1,034.337 millions
Macrogenics Inc  1,030.49 %$ 1,030.492 millions
Genesis Healthcare, Inc.  917.00 %$ 917.001 millions
Quest Patent Research Corp  876.64 %$ 876.639 millions
Revance Therapeutics, Inc.  814.67 %$ 814.667 millions
Enanta Pharmaceuticals Inc  662.38 %$ 662.375 millions
Tetraphase Pharmaceuticals Inc  630.08 %$ 630.076 millions
Bioscrip, Inc.  606.00 %$ 605.996 millions
Blueprint Medicines Corp  603.55 %$ 603.548 millions
Reshape Lifesciences Inc.  602.09 %$ 602.094 millions
Pieris Pharmaceuticals, Inc.  530.97 %$ 530.971 millions
Bionik Laboratories Corp.  472.82 %$ 472.821 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

EVOL's Profile

Stock Price

EVOL's Financials

Business Description

Fundamentals

Charts & Quotes

EVOL's News

Suppliers

EVOL's Competitors

Customers & Markets

Economic Indicators

EVOL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us



CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071